By Douglas "Doug" D. Salyers , James Moore Bollinger , George B. Snyder
and Robert "Rob" E. Browne, Jr.
Last week, the Court of Appeals for the Federal Circuit held that
certain isolated human DNA molecules are eligible for patent protection.
This was an important decision...
On July 29, 2011, a divided panel of the United States Court of
Appeals for the Federal Circuit, in an appeal from the United States
District Court for the Southern District of New York, issued its
highly-anticipated decision in Association for Molecular Pathology v. U.S. Patent & Trademark...
By Vincent Y. Ling*
*J.D. and Masters of Bioethics Candidate, 2012, University
Excerpt from Patently Ours? Constitutional Challenges to
DNA Patents , 14 U. Pa. J. Const. L. 813 (February, 2012)
The controversy surrounding patenting deoxyribonucleic acid
Patentable Subject Matter Challenge Advanced in Patent Reexamination
This past March, as most in the patent community are well aware, the Supreme Court recalibrated 35 U.S.C. § 101 in Mayo Collaborative Services v. Prometheus . The decision held that certain patents of Prometheus Laboratories...
On Sept. 21, 2012, a three-judge panel of the Federal Circuit in In re Droge (2011-1600) [ enhanced version available to lexis.com subscribers ] held that the claims in U.S. patent application serial no. 10/082,772 (the '772 application"), directed to a method of recombining DNA in eukaryotic...
By Nancy Wilker, Ph.D . A member of the Life Sciences Practice Group
Two thousand thirteen may end up being the year of life sciences patent law at the Supreme Court. In the last three months, the court has agreed to hear three biotech/pharma cases, the outcomes of which will have sweeping implications...